Literature DB >> 27993551

Dose-response of serum 25-hydroxyvitamin D in association with risk of colorectal cancer: A meta-analysis.

Cedric F Garland1, Edward D Gorham2.   

Abstract

Fifteen nested case-control or cohort studies in 14 countries have examined the association between serum 25-hydroxyvitamin D [25(OH)D] and risk of colorectal cancer. A meta-analysis of these studies would provide a useful dose-response gradient curve based on pooling of the results of known studies to date. An up-to-date dose-response curve that combines the findings of these studies has not been reported, to our knowledge. This curve would help in designing interventions for future studies. A new meta-analysis would be more precise than any previous analysis due to its larger sample size. Therefore a search of PubMed and other resources was performed in May 2016 for all cohort or nested case-control observational studies that reported risk of colon or colorectal cancer by quantiles of 25(OH)D. All but two of the 15 studies found a trend toward lower risk of colorectal cancer associated with higher serum 25(OH)D. There was a linear reduction in the odds ratio (OR) with each 10ng/ml-increment in 25(OH)D concentration. The lowest quantile of the serum 25(OH)D concentration was generally<20ng/ml. The downward trend in ORs associated with higher serum 25(OH)D concentrations was statistically significant in 3 studies. The pooled OR from all studies comparing highest with lowest quantile of 25(OH)D was 0.67 (95% confidence interval [CI], 0.59-0.76), meaning there was a 33% lower risk associated with the highest compared with the lowest quantile of serum 25(OH)D. A dose-response analysis revealed that a serum 25(OH)D of 50ng/ml was associated with an OR of 0.4 (95% CI, 0.2-1.0) compared with a concentration of 5ng/ml. The formula for the linear relationship was OR=0.008x. For example, individuals with a 25(OH)D concentration of 50ng/ml had an approximately 60% lower risk of colorectal cancer than those with a concentration of 5ng/ml. Those with a 25(OH)D concentration of 30ng/ml had a 33% lower risk than those with a concentration of 5ng/ml. The inverse association between serum 25(OH)D and risk of colorectal cancer overall was strong and statistically significant. There also was a mostly linear dose response relationship between serum 25(OH)D and risk of colorectal cancer when all studies were combined. No study reported significant adverse effects, and there was no evidence of publication bias. Misclassification in some studies could have influenced the association, causing it to appear weaker than the true association.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  25-Hydroxyvitamin D; Colorectal cancer; Dose-response; Meta-analysis

Mesh:

Substances:

Year:  2016        PMID: 27993551     DOI: 10.1016/j.jsbmb.2016.12.003

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  25 in total

1.  The association of gastrointestinal cancers (esophagus, stomach, and colon) with solar ultraviolet radiation in Iran-an ecological study.

Authors:  Esmail Najafi; Narges Khanjani; Mohammad Reza Ghotbi; Mohammad Esmaeil Masinaei Nejad
Journal:  Environ Monit Assess       Date:  2019-02-09       Impact factor: 2.513

2.  Vitamin D supplementation for prevention of cancer: The D2d cancer outcomes (D2dCA) study.

Authors:  Ranee Chatterjee; John K Erban; Paul Fuss; Rowena Dolor; Erin LeBlanc; Myrlene Staten; Patricia Sheehan; Anastassios Pittas
Journal:  Contemp Clin Trials       Date:  2019-04-29       Impact factor: 2.226

3.  Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.

Authors:  Marissa B Savoie; Alan Paciorek; Li Zhang; Erin L Van Blarigan; Nilli Sommovilla; Donald Abrams; Chloe E Atreya; Emily K Bergsland; Hueylan Chern; Robin K Kelley; Andrew Ko; Angela Laffan; Ankit Sarin; Madhulika G Varma; Alan P Venook; Katherine Van Loon
Journal:  J Gastrointest Cancer       Date:  2019-12

4.  Association Between Dairy Product Consumption and Colorectal Cancer Risk in Adults: A Systematic Review and Meta-Analysis of Epidemiologic Studies.

Authors:  Laura Barrubés; Nancy Babio; Nerea Becerra-Tomás; Núria Rosique-Esteban; Jordi Salas-Salvadó
Journal:  Adv Nutr       Date:  2019-05-01       Impact factor: 8.701

Review 5.  Vitamin D3 from Ultraviolet-B Exposure or Oral Intake in Relation to Cancer Incidence and Mortality.

Authors:  William B Grant; Meis Moukayed
Journal:  Curr Nutr Rep       Date:  2019-09

Review 6.  Newly-identified Pathways Relating Vitamin D to Carcinogenesis: A Review.

Authors:  Nadeem Bilani; Leah Elson; Charles Szuchan; Elizabeth Elimimian; Mustafa Saleh; Zeina Nahleh
Journal:  In Vivo       Date:  2021-04-28       Impact factor: 2.406

7.  Circulating vitamin D concentration and risk of prostate cancer: a dose-response meta-analysis of prospective studies.

Authors:  Jialin Gao; Wei Wei; Gang Wang; Honglan Zhou; Yaowen Fu; Nian Liu
Journal:  Ther Clin Risk Manag       Date:  2018-01-09       Impact factor: 2.423

8.  Plasma 25-hydroxyvitamin D concentration and subsequent risk of total and site specific cancers in Japanese population: large case-cohort study within Japan Public Health Center-based Prospective Study cohort.

Authors:  Sanjeev Budhathoki; Akihisa Hidaka; Taiki Yamaji; Norie Sawada; Sachiko Tanaka-Mizuno; Aya Kuchiba; Hadrien Charvat; Atsushi Goto; Satoshi Kojima; Natsuki Sudo; Taichi Shimazu; Shizuka Sasazuki; Manami Inoue; Shoichiro Tsugane; Motoki Iwasaki
Journal:  BMJ       Date:  2018-03-07

Review 9.  Associations between nutritional factors and KRAS mutations in colorectal cancer: a systematic review.

Authors:  Achraf El Asri; Btissame Zarrouq; Khaoula El Kinany; Laila Bouguenouch; Karim Ouldim; Karima El Rhazi
Journal:  BMC Cancer       Date:  2020-07-28       Impact factor: 4.430

10.  Genome-Wide Association Study of Serum 25-Hydroxyvitamin D in US Women.

Authors:  Katie M O'Brien; Dale P Sandler; Min Shi; Quaker E Harmon; Jack A Taylor; Clarice R Weinberg
Journal:  Front Genet       Date:  2018-03-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.